A rare case of long-term immune depletion in children following chemotherapy for acute leukemia: secondary or primary immunodeficiency?
Case presentation A 12-yo girl was diagnosed at the age of 3 […]
Treatment
Role of Quality by Design in the manufacturing process of Tegeline® and its impact on final formulation
Tegeline ® manufacturing process was developed based on new guidance / recommendations
A rare case of long-term immune depletion in children following chemotherapy for acute leukemia: secondary or primary immunodeficiency?
A 12-year-old girl was diagnosed at the age of 3 (2014) with
First steps with facilitated subcutaneous immunoglobulin (fSCIg) therapy in a center from Argentina
Introduction: Several studies have shown that facilitated subcutaneous immunoglobulin (fSCIg) is as
Use of subcutaneous immunoglobulin 16% in critical pediatric patients under 10 kg in a reference hospital in Colombia
Introduction: Subcutaneous immunoglobulin (SCIG) has gained popularity as a route for immunoglobulin
OTHER USES IMMUNOGLOBULIN INTRAVENOUS IN PATIENT WHIT GATA 2 DEFFICIENCY
Introduction: We present the case of a patient with GATA 2 Deficiency
OTHER USES IMMUNOGLOBULIN INTRAVENOUS IN PATIENT WHIT GATA 2 DEFFICIENCY Read More »
COVID-19 IN A PATIENT WITH TNTR1 DEFECT TREATED WITH NIRMATRELVIR/RITONAVIR.
Introduction: A patient with TNRT1 defect with COVID-19 infection, was treated with
COVID-19 IN A PATIENT WITH TNTR1 DEFECT TREATED WITH NIRMATRELVIR/RITONAVIR. Read More »
Tolerability and safety of intravenous immunoglobulins (5% and 10%) for the treatment of patients with secondary immunodeficiencies – Final subgroup results of a non-interventional safety study
Introduction: Hematological diseases and/or its immunosuppressive treatments can cause secondary immunodeficiencies (SID).
